Abstract: Objective To evaluate the efficacy and adverse effects of cetuximab combined with FOLFIRI regimen for advanced colorectal cancer with K-Ras wild-type patients. Methods From January 2008 to June 2010，44 patients with K-Ras wildtype advanced colorectal cancer proved by pathology were treated with cetuximab biweekly plus FOLFIRI regimen.Cetuximab was given by 500mg／m2iv every 2 weeks，irinotican 180mg／m2 iv dl，calcium folinate 200mg／m2 iv dl，fluorouracil 400mg／m2 ivp dl and then 2400mg／m2 civ 46h. Every 2 weeks was a cycle.All the patients recieved at least 4 cycles of chemotherapy.Adverse reaction was assessed by the NCI CTC 3.0 standard. Results In 44 patients，2 cases received CR（4.6％），22 cases PR（50.0％），17 cases SD（38.6％），3 cases PD（6.8％），the response rate（RR）was 54.6％and disease control rate（DCR）was 93.2％.The univariate analysis showed that RR was related to primary site，but not with gender，age，number of metastatic organs，metastatic sites and ECOG score，and DCR was not related to any clinical features. Logistic regression analysis showed that primary site was the independent factor influencing RR（P=0.0455）. The median overall survival（OS）was 25.7 months（95％CI：20.5-34.6months），and the median progressionfree survival （PFS）was 8.4 months（95％CI：6.3-11.7months）. The Cox regression model showed that ECOG score was the independent influential factor of PFS，and gender influenced OS. The common adverse events were skin rash，digestive reaction and neutropenia，mainly in grade 1-2. Conclusion Cetuximab combined with FOLFIRI regimen every 2 weeks for the patients with advanced colorectal cancer is effective，and the adverse effect is tolerable，worth further study.